Replies to post #711431 on NorthWest Biotherapeutics Inc (NWBO)

[ae kusterer]

vator :please post the NCT for "the rececnt Keytruda combo trail". thanks.

Re: brazen22 post# 711430

Thursday, August 08, 2024 5:50:06 AM

Post#
711431
of 711434
First look combination combination studies with a TLR agonist leads to 50% over 5 year survival for nGBM. With Keytruda rGBM has led to 60% cure rate.

If you continue to take a myopic view you will lose. Recent Keytruda combo is due to finish this month. Usually these things are never on time. But, when finished, I bet they file with the FDA with conditional studies without going through a phase III.

And as a solo therapy it is still better than SOC. The UK will approve. They would not be conducting inspections otherwise. Without the data being a plus, they would not be performing inspections.

[skitahoe]

Biosect, is there any way the regulators can look at what's obvious to everyone else and approve the use of Poly-ICLC along with DCVax-L. I've always felt that regulators should be able to make such moves, even though it violates their regulations. When it's obvious that a major stride has been achieved, why insist on years of additional trials plus the time needed to apply and evaluate to approve something that's obvious years before.

Don't get me wrong, I really don't believe patients will have no trouble getting Poly-ICLC and having insurance cover it, but why not approve it and end all the debate.

Gary